Strengthening Europe’s Pharma Market Access Environment

João L. Carapinha, Ph.D.

Table of Contents

Poll 25 – 2026

23
Strengthening Europe’s Pharma Market Access Environment

I’ve been thinking about how market access decisions now affect not only patient access, but also R&D investment, clinical trial activity, and Europe’s broader competitiveness. If Europe wants to improve both access and investment, what should come first? Share your insights by voting below!

 

What should be the top priority for improving pharma market access in Europe?

Table of Contents